Live Breaking News & Updates on Alnylam Pharmacauticals|Page 1

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am ....

Rio De Janeiro , Estado Do Rio , United States , New Zealand , Cidade Universitaria , Alnylam Pharmacauticals , Marques Jr , Clementino Fraga Filho , Waddington Cruz , Ionis Astrazeneca , Rodolpho Paulo Rocco , Intellia Regeneron , Research To Practice , American Academy Of Neurology Annual Meeting , Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , University Of Rio De Janeiro , Aptitude Health , Bristol Myers Squibb , Novo Nordisk , Group Information , Drug Administration , Alnylam Pharmaceuticals , Peripheral Nerve Society Annual Meeting , International Council For Harmonisation , Mayo Clinic Peripheral Nerve Research Laboratory ,